Will Cronos (TSX:CRON) and Altria (NYSE:MO) Take Over the Cannabis Market?

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) and Altria Group Inc (NYSE:MO) partnership could be a force to be reckoned with.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Few cannabis stocks are better positioned than Cronos Group (TSX:CRON)(NASDAQ:CRON). That’s because it has the backing of one of the most powerful, well-financed, most influential companies on the planet: Altria Group (NYSE:MO).

Today, Altria is responsible for more than half of all U.S. cigarette sales. Its market cap exceeds $100 billion. That’s larger than every Canadian pot stock combined.

With a $3 billion valuation, investors are hoping that Altria can help Cronos become the next cannabis giant. If it ever achieved the same scale as Altria, Cronos shareholders would experiences gains in excess of 3,000%.

Following its US$1.8 billion investment last year, Altria has plenty to lose if things go sour. That’s exactly why this partnership could end up taking over the entire cannabis market.

This is the pitch

The pot market seems to move at light speed. So much can occur in just a few months. That’s why it make sense to go back to the original rationale for Altria’s investment in Cronos. Their joint presentation was released fewer than 14 months ago, but few cannabis investors bother digging it up.

The biggest aspect of the pitch was the synergy potential. Altria would be providing proven expertise in brand and product development in highly regulated markets, financial capacity to support growth, plus industry-leading research and development capabilities. Cronos, meanwhile, was already one of the largest cannabis producers in the world, with the team and infrastructure in place to scale rapidly.

In total, Altria took a 45% position in Cronos, with warrants that allow it to increase its ownership to 55% down the road. The investment was made at a 30-40% premium to prevailing prices.

This deal instantly gave Cronos more credibility than all of its competitors. Armed with $2.5 billion in cash and a global distribution network, shareholders expected the company to take off.

Revisit the assumptions

Cronos stock did take off for a bit. From November 2018 to March 2019, shares nearly tripled in value. When the cannabis bear market hit that spring, however, no pot stock was spared. Since March, Cronos stock has dropped from $30 to just $10.

After the decline, Cronos shares now trade below the price Altria paid. If you’re looking to put more capital to work, this may be your top opportunity.

Cronos stock now has a valuation of $3.3 billion. Compare that to legal marijuana sales, which are expected to surpass $100 billion globally by 2030. Some analysts expect worldwide sales to eventually surpass $250 billion. That’s not surprising considering worldwide tobacco sales surpass $1 trillion.

Even after the drop, this stock looks expensive. It trades at roughly 65 times 2019 earnings. But sales are just beginning to ramp. Based on expected revenues for 2020, the stock trades at 19 times forward sales. That’s still pricey, but you start to appreciate how this stock could quickly become cheap.

Armed with its Altria partnership, it’s difficult to see how Cronos doesn’t become a major player in both the Canadian and U.S. markets. Marijuana Business Daily expects U.S. sales to triple to $30 billion by 2023. Full legalization could quadruple that figure quickly.

How much of a share will the Cronos-Altria partnership garner? My bet is a lot, certainly more than is currently priced in. This bet may take a few years to pay off, but it represents one of the best risk/reward tradeoffs in the cannabis industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »